{"id":"NCT01131065","sponsor":"Instituto Grifols, S.A.","briefTitle":"Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients","officialTitle":"Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2010-05-26","resultsPosted":"2016-02-01","lastUpdate":"2016-02-25"},"enrollment":15,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B","Liver Transplantation"],"interventions":[{"type":"DRUG","name":"Hepatitis B immune globulin","otherNames":["Niuliva"]}],"arms":[{"label":"Hepatitis B immune globulin","type":"EXPERIMENTAL"}],"summary":"The aim of this clinical trial is to evaluate the efficacy, safety, and tolerability of Niuliva (Hepatitis B virus immune globulin) in the prophylaxis of hepatitis B virus (HBV) reinfection in patients submitted to liver transplantation due to HBV-induced liver disease by reaching and maintaining certain hepatitis B antibody (HBsAg) levels considered as protective during the first six and twelve months post-transplantation.","primaryOutcome":{"measure":"HBV Recurrence","timeFrame":"First six and twelve months after liver transplantation","effectByArm":[{"arm":"Hepatitis B Immune Globulin","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":13},"locations":{"siteCount":4,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":15},"commonTop":["Sleep disorders","Hypertension","Anemia","Tremor","Renal failure acute"]}}